Psychedelics

A single dose of psilocybin was associated with a significant and sustained reduction in depressive symptoms and possible improvement of PTSD and burnout experienced by clinicians from the front line of the COVID-19 pandemic.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Here are highlights from this week in Psychiatric Times, including conference updates and trial news.

New phase 3 data on CYB003 is coming. Learn more about the phase 3 pivotal program here.

We asked our contributors at the 63rd meeting of the American College of Neuropsychopharmacology what they are excited about from 2024 and what they are looking forward to in 2025. Here's what they said.

With MM120 in phase 3 in the MindMed trial, what place do psychedelics hold in psychiatry?

New positive topline results from an open-label phase 2a study of IV psilocin benzoate in patients with major depressive disorder showed that the treatment delivers rapid, lasting antidepressant effects for up to 3 months following a single dose.

MindMed announced phase 3 study of psychedelic MM120 for Generalized Anxiety Disorder.

MindMed announced phase 3 of a trial testing a new treatment for generalized anxiety disorder is under way.

Post-hoc analysis of the ELEKT-D trial of ketamine and ECT for patients with treatment-resistant depression distinguishes between responders to the respective interventions.

How does ketamine-assisted psychotherapy help real world patients?

Psychiatrists are trying our ketamine-assisted psychotherapy in their clinical practices. What do patients think of this treatment?

Dr Miller continues her Ketamine Journal with a mini-group of 2 patients and a cofacilitator.

John Krystal, MD, explores the future of ketamine and psychedelics in psychiatry, shedding light on their potential to improve patient care by increasing options treatment options.

Should ketamine be used at all when FDA-approved Spravato is available and insurance will pay for it?

Psychedelics: we first must enlarge our knowledge of how these work, what clinical conditions should be targeted, and how different psychedelics compare to each other.

The FDA instead issued a CRL for MDMA-assisted psychotherapy for PTSD, requesting an additional phase 3 trial to examine safety and efficacy. Other psychedelic compounds are proceeding with trials for psychiatric conditions. Learn more here.

While new treatment options in the PTSD space can be exciting, we cannot lose sight of the treatments that are already readily available.

New phase 1b results of VLS-01, an oral transmucosal film formulation of DMT, show ‘psychologically meaningful’ improvement for patients with treatment-resistant depression.

A phase 3 clinical trial participant shares her thoughts on MDMA-assisted psychotherapy and her trial experience.

Despite the FDA's complete response letter for MDMA-assisted psychotherapy, researchers believe the data behind this PTSD treatment is what matters most.

At least 1 in 2 people experience trauma at some point in their life, and a subset of those individuals will develop PTSD.

After months of preparation, one psychiatrist starts using KAP in her practice.

A mainstream psychiatrist finds herself exploring a treatment that is off the radar for most.

Psychedelics may catalyze rapid improvements in mental health, but they do so firmly rooted in what we already know about the efficacy of psychotherapy.

Learn more about one psychiatrist’s personal experiential learning process with ketamine.

The FDA did not vote to deny approval of MDMA-assisted psychotherapy on June 4, 2024, contrary to all the buzz in the media saying they did. Learn more here.

Here are highlights from the week in Psychiatric Times.

June held negative news for psychedelics and an accepted sNDA for brexpiprazole + sertraline for adults with PTSD.